Cargando…

Single-Cell Analyses of a Novel Mouse Urothelial Carcinoma Model Reveal a Role of Tumor-Associated Macrophages in Response to Anti-PD-1 Therapy

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) have been standard care for advanced bladder cancer patients who fail or are not eligible for chemotherapy. There is an urgent need for preclinical models to study immunotherapy responses because the majority of patients with advanced bladder cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Dongbo, Wang, Li, Wieczorek, Kyle, Zhang, Yali, Wang, Zinian, Wang, Jianmin, Xu, Bo, Singh, Prashant K., Wang, Yanqing, Zhang, Xiaojing, Wu, Yue, Smith, Gary J., Attwood, Kristopher, Zhang, Yuesheng, Goodrich, David W., Li, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139541/ https://www.ncbi.nlm.nih.gov/pubmed/35626115 http://dx.doi.org/10.3390/cancers14102511

Ejemplares similares

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021)

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
por: Zeng, Dongqiang, et al.
Publicado: (2020)

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
por: Wang, Jianzheng, et al.
Publicado: (2021)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer
por: Wu, Xuehui, et al.
Publicado: (2021)

Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer
por: Chen, Siteng, et al.
Publicado: (2019)

Genome-Wide Analyses of Prognostic and Therapeutic Alternative Splicing Signatures in Bladder Urothelial Carcinoma
por: Fan, Zhongru, et al.
Publicado: (2021)

MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity
por: Chinnam, Meenalakshmi, et al.
Publicado: (2022)

Correction: MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity
por: Chinnam, Meenalakshmi, et al.
Publicado: (2022)

Effects of cooking methods on total isothiocyanate yield from cruciferous vegetables
por: Wang, Zinian, et al.
Publicado: (2020)

Trends of incidence and prognosis of upper tract urothelial carcinoma
por: Wu, Jianping, et al.
Publicado: (2021)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
por: Ding, Xiangli, et al.
Publicado: (2019)

Serum Androgen Metabolites Correlate with Clinical Variables in African and European American Men with Localized, Therapy Naïve Prostate Cancer
por: Ramakrishnan, Swathi, et al.
Publicado: (2023)

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2022)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
por: Sun, Fengze, et al.
Publicado: (2022)

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
por: Ciamporcero, Eric, et al.
Publicado: (2015)

The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials
por: Li, Fei, et al.
Publicado: (2021)

Targeting of CCN2 suppresses tumor progression and improves chemo-sensitivity in urothelial bladder cancer
por: Wang, Xiaojing, et al.
Publicado: (2017)

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2023)

Genetic and phylogenetic analyses of the first GIII.2 bovine norovirus in China
por: Shi, Zhihai, et al.
Publicado: (2019)

Immune escape mechanisms and immunotherapy of urothelial bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer
por: Li, Pengju, et al.
Publicado: (2021)

MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5
por: Xu, Tianyuan, et al.
Publicado: (2016)

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
por: Wang, Li, et al.
Publicado: (2018)

Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials
por: Parmar, Kanak, et al.
Publicado: (2022)

Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses
por: Li, Jing, et al.
Publicado: (2019)

Integrated proteogenomic characterization of urothelial carcinoma of the bladder
por: Xu, Ning, et al.
Publicado: (2022)

Poor prognostic value of lymphovascular invasion for pT1 urothelial carcinoma with squamous differentiation in bladder cancer
por: Li, Gang, et al.
Publicado: (2016)

Metabolite profiling and transcriptome analyses provide insight into the regulatory network of graft incompatibility in litchi
por: Hou, Yanjie, et al.
Publicado: (2023)

Mutational signature and clonal relatedness of recurrent urothelial carcinomas with aristolochic acid
por: Zhu, Jie, et al.
Publicado: (2022)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review
por: Li, Shihao, et al.
Publicado: (2022)

Clinicopathological and prognostic value of long noncoding RNA SNHG7 in cancers: a meta-analysis and bioinformatics
por: Wang, June, et al.
Publicado: (2021)

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
por: Lu, Yiran, et al.
Publicado: (2023)

Protein Profiling of Bladder Urothelial Cell Carcinoma
por: Hu, Jinghai, et al.
Publicado: (2016)

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
por: Wang, Yue, et al.
Publicado: (2023)

Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma
por: Huang, Tzu-Hao, et al.
Publicado: (2021)

AB162. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma
por: Xiong, Gengyan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bs7p3vhup2fce1qp9chp35u49g